Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetLife, Inc. (NYSE: MET) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-supported tools to help interpret them. MetLife is a global financial services company offering insurance, annuities, employee benefits and asset management, with operations in more than 40 markets and leading positions in the United States, Asia, Latin America, Europe and the Middle East.
Investors can review current reports on Form 8-K, where MetLife discloses material events such as earnings announcements, segment reorganizations, acquisitions, reinsurance transactions and dividend declarations. Recent 8-K filings describe the designation of MetLife Investment Management (MIM) as a reportable segment, the reclassification of MetLife Holdings, the acquisition of PineBridge Investments, and a variable annuity reinsurance transaction with Talcott Resolution Life Insurance Company. Other 8-Ks address preliminary variable investment income information, preferred stock matters, and the company’s response to an unsolicited mini-tender offer.
Through this page, users can also locate quarterly and annual reporting materials referenced in MetLife’s filings, such as earnings releases, Quarterly Financial Supplements, total assets under management fact sheets and historical results supplements. These documents provide detail on segment performance across Group Benefits, Retirement and Income Solutions, regional insurance operations and MetLife Investment Management, as well as information on variable investment income and capital management.
Stock Titan’s platform enhances these filings with AI-powered summaries that explain key terms, highlight important changes and help clarify how specific disclosures may relate to MetLife’s broader business. Users can quickly identify items related to dividends, capital structure, segment changes, asset management acquisitions and risk transfer transactions without reading every line of each filing.
MetLife accounts filed a notice on Form 144 to sell 231 shares of common stock through Barclays on the NYSE, with an aggregate market value of $19,006.68. This is a small number of shares compared with 658,891,656 shares outstanding.
The shares were originally purchased for cash on 12/17/2019 from Bank of America, with payment made on 12/19/2019. The filing also lists several prior common stock sales over the past three months by MetLife retirement and separate accounts, including 333 shares sold by the MetLife 401k Plan Trust-Large Cap Equity Index for $27,282.69 and 335 shares sold by Separate Account SPI for $25,563.85.
MetLife, Inc. reported that one of its directors acquired additional common stock through a routine plan-related transaction. On 12/09/2025, the director obtained 687 shares of MetLife common stock at $77.82 per share, described as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director beneficially owns 102,754 shares of MetLife common stock in direct form.
A MetLife, Inc. director reported a small increase in holdings through automatic dividend reinvestment under the company’s Deferred Compensation Plan for Non-Management Directors. On 12/09/2025, the director acquired 11 shares of MetLife common stock at $77.82 per share via an imputed reinvestment of dividends on deferred shares. Following this transaction, the director beneficially owns 1,469 shares of MetLife common stock in direct form. The transaction was reported on a Form 4 as required for company insiders.
MetLife, Inc. director reports additional common stock from dividend reinvestment. On 12/09/2025, the director acquired 324 shares of MetLife common stock at $77.82 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. After this transaction, the director beneficially owned 44,776 shares directly and 10 shares indirectly through the MetLife Policyholder Trust, which holds stock allocated to eligible policyholders of Metropolitan Life Insurance Company.
MetLife, Inc. reported a small insider activity by one of its directors. On 12/09/2025, the director acquired 54 shares of MetLife common stock through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a price of $77.82 per share. Following this automatic dividend reinvestment, the director directly beneficially owns 7,425 shares of MetLife common stock.
MetLife, Inc. director reported a routine change in ownership of common stock linked to a compensation plan. On 12/09/2025, the director acquired 31 shares of MetLife common stock at $77.82 per share through imputed dividend reinvestment on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director directly beneficially owned 4,292 MetLife common shares. The filing notes that deferred shares are amounts that have become payable but that the director has chosen to defer receiving.
MetLife, Inc. filed a Form 4 reporting that one of its directors acquired additional common shares through an automatic dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors. On 12/09/2025, the director was credited with 166 shares of MetLife common stock at a price of $77.82 per share, described as imputed reinvestment of dividends on deferred shares. Following this transaction, the director beneficially owned 22,923 MetLife common shares in direct form.
MetLife, Inc. reported a small insider share acquisition by one of its directors. On 12/09/2025, the director acquired 34 shares of MetLife common stock at $77.82 per share, increasing the director’s beneficial ownership to 9,082 shares, held directly.
The transaction reflects imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Under this plan, directors can defer receipt of shares that have become payable, with dividends on those deferred shares reinvested in additional deferred share units.
MetLife, Inc. filed a current report to disclose that, on December 1, 2025, it completed its previously announced transaction with Talcott Resolution Life Insurance Company to reinsure approximately
The completion of this transaction is communicated under a Regulation FD disclosure, with further details provided in a related news release that is attached as an exhibit and incorporated by reference.
MetLife-related accounts have filed a Form 144 to sell a small block of common stock. The notice covers a proposed sale of 335 shares of MetLife common stock through Wells Fargo, with an aggregate market value of 25,647.6, on the New York Stock Exchange on or about 12/01/2025. The issuer had 658,891,656 shares outstanding at the time referenced.
The seller acquired the 335 shares in a cash purchase from Goldman Sachs on 05/29/2015, with payment made on 06/03/2015. Over the past three months, several MetLife-related accounts, including Separate Account II, Separate Account SPI, Separate Account 149, the MetLife 401k Plan Trust-Large Cap Equity Index, and the MetLife 401k Plan Russell 1000 Value, sold additional blocks of MetLife common stock in multiple transactions, with gross proceeds for individual trades ranging from 1,345.72 to 27,282.69.
FAQ
What is the current stock price of MetLife (MET)?
What is the market cap of MetLife (MET)?
